# NOVANTA INC (NOVTU) — capital_raise [completed]
Source: SEC API (secapi.ai) · situation sit_7cdc929b6873e420bf5e · retrieved 2026-08-11T15:59:13.399Z

## Overview
Novanta Inc. is a leading global supplier of core technology solutions to medical, life science, and advanced industrial original equipment manufacturers, combining expertise in precision medicine, precision manufacturing, robotics, automation, and advanced surgery.

Novanta Inc. completed its acquisition of Riverpoint Medical from Arlington Capital Partners on July 23, 2026. At closing, Novanta paid approximately $1.2 billion in cash, subject to customary adjustments for cash, working capital, debt, and transaction expenses. An additional milestone payment of $250.0 million is payable by January 8, 2027. To fund the transaction, Novanta's Intermediate Parent borrowed $616.0 million under its revolving credit facility and delayed draw term loan facility, with borrowings due in June 2030. Riverpoint Medical is a category leader in minimally invasive surgical consumables, and the acquisition is expected to double Novanta's recurring medical consumables revenue to approximately $300 million.

## Terms
- Counterparty: Arlington Capital Partners (seller of Riverpoint Medical) · Consideration: cash

## Key dates
- Completed 2026-07-23

## Timeline
- 2026-07-27 · 8-K (0001193125-26-316947): 8-K - NOVANTA INC — *Novanta Inc. is a leading global supplier of core technology solutions to medical, life science, and advanced industrial original equipment manufacturers, combining expertise in precision medicine, precision manufacturing, robotics, automation, and advanced surgery.* Novanta Inc. completed its acquisition of Riverpoint Medical from Arlington Capital Partners on July 23, 2026. At closing, Novanta paid approximately $1.2 billion in cash, subject to customary adjustments for cash, working capital, debt, and transaction expenses. An additional milestone payment of $250.0 million is payable by January 8, 2027. To fund the transaction, Novanta's Intermediate Parent borrowed $616.0 million under its revolving credit facility and delayed draw term loan facility, with borrowings due in June 2030. Riverpoint Medical is a category leader in minimally invasive surgical consumables, and the acquisition is expected to double Novanta's recurring medical consumables revenue to approximately $300 million.
  https://www.sec.gov/Archives/edgar/data/1076930/0001193125-26-316947.txt

## Citations
- 0001193125-26-316947 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526316947